118results about How to "High diagnostic value" patented technology

The invention relates to a method for acquiring and evaluating vascular examination data, comprising: acquisition of IVUS images of a vessel to be examined using an IVUS catheter; simultaneous acquisition of angiography data of the IVUS catheter having at least one angiography marker; acquisition of OCT images of the same point of the vessel to be examined using an OCT catheter; simultaneous acquisition of angiography data of the OCT catheter having at least one angiography marker; registering the IVUS and OCT images; determination of contours of the structures of the vessel under examination based on the OCT images; arithmetic histological analysis of the co-registered IVUS and OCT images using the information about the contours; and display the results.

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

In a method for imaging a periodically-moving subject region of a subject, an overview image data set is initially obtained that maps a movement of the subject region, at least two positions that the subject region assumes at corresponding points in time are marked in the overview image, further positions of the subject region at further points in time are interpolated from the marked positions and further points in time, and a subsequent diagnostic imaging of the moving subject region is implemented using the marked and interpolated positions.

In accordance with the present invention a luminescent article is provided, which luminescent article comprises a self-supporting or supported layer of phosphor particles dispersed in a binding medium and, adjacent thereto, a protective coating characterized in that, besides a binder, the said protective coating comprises as a white pigment titanium dioxide, which is present in the said binder, preferably further comprising an urethane acrylate, and wherein said protective coating has a surface roughness (Rz) between 2 and 10 mum.

The invention discloses a miRNA marker in a serum exosome related to early diagnosis of lung adenocarcinoma and application. The marker is selected from hsa-miR-4516, hsa-miR-342-3p, hsa-miR-199a-3p, hsa-miR-150-5p, hsa-miR-140-3p, hsa-miR-18a-5p, hsa-miR-222-3p, hsa-miR-27a-3p, hsa-miR-29a-3p, hsa-miR-221-3p, hsa-miR-500a-3p, hsa-miR-6126 and hsa-miR-6715a-3p. The marker can effectively separate early lung adenocarcinoma cases from healthy people. The marker and probes thereof can be used for preparing a lung adenocarcinoma early diagnosis kit. The marker has an assisting effect on early diagnosis of lung adenocarcinoma.

The invention belongs to the biotechnical field and relates to a plasma miRNA marker for diagnosis of lung cancer and application. The invention provides the plasma miRNA marker for diagnosis of lung cancer. The marker comprises miRNA-486, miRNA-150, miRNA-205 and miRNA-210. The invention further provides primer probes shown in sequences SEQ ID NO. 1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 as well as application of the primer probes in preparation of kits for diagnosis of lung cancer. The marker provided by the invention has the beneficial effects that a biomarker which has a relatively high diagnostic value on lung cancer is found, and the biomarker has a relatively high diagnostic value (AUC is 0.975, and the sensitivity and specificity are respectively 90.9% and 100%).

The invention relates to the field of biological detection, particularly to a group of microRNA biological markers for early lung cancer diagnosis and an application thereof. The microRNA biological marker comprises hsa-miR-125a-5p, hsa-miR-193a-5p, hsa-miR-25, hsa-miR-126 and hsa-miR-34a. The serum miRNA biological markers comprising the 5 miRNAs can not only be particularly applied to early lung cancer detection, but also be applied to advanced lung cancer detection.

The invention discloses a liver cancer diagnostic kit based on nucleic acid aptamers, comprises the following ingredients with independent packing: liver cancer nucleic acid aptamer solution, polyacrylamide gel mother liquor, ammonium persulfate, tetramethyl diethylamine, 50% glycerin solution II, 1.25M sodium chloride solution, GelRed dye solution, positive control serum, and negative control serum. The kit has the following characteristics: (1) high diagnostic value, sensitivity of about 85%, specificity of about 85%, and accuracy of about 85%; (2) simpleness and practicality, and only need of conventional vertical electrophoresis and a gel image analysis system to realize the diagnosis; and (3) low cost and high additional value. Liver cancer is one of common malignant tumors in clinic, thus by applying the kit of the invention in clinical application, the consumption is high, the diagnostic level of liver cancer can be effectively raised, good economic benefit and social benefit can be produced, and the application prospect is good.

A late potential detecting system has an implantable medical device connected to at least one cardiac lead having implantable electrodes positioned at different sites of a ventricle myocardium. A sampling unit of the implantable medical device records electrogram samples for the different implantable electrodes to get different sample sets. The electrogram samples of the sample sets are time synchronized and magnitude potential representations of the potential data of the electrogram samples are determined. The magnitude potential representations of the time synchronized electrogram samples are then co-processed and used for determining a parameter that is indicative of any late potentials of the monitored ventricle.

The invention relates to the field of digital processing of X-ray images and can be used in digital subtraction angiography to compensate for impact of involuntary patient movement and movement of internal organs on image of the vascular system. The technical result of the claimed invention is the improvement of diagnostic value of subtraction angiographic images by eliminating artifacts caused by the motility of anatomical structures. Technical result is achieved by the that at the stage of digital images registration a search for characteristic details is performed for each image. According to the shift of the said details determine expectable shift of a patient organs. Then perform segmentation of image from the pre-contrast series in the region of homogenous warping ; for each region a geometrical transformation is calculated and corresponding geometrical transformations are performed for each region of a series of pre-contrast digital images. This means vessels visibility enhancement and treatment and diagnostic improvement.

The invention relates to a method for detecting the content of total alpha-synuclein combined with hemoglobin in erythrocytes of blood. The method comprises the following steps: taking an anti-human hemoglobin monoclonal antibody as a capturing antibody; taking an anti-human alpha-synuclein monoclonal antibody as a detection antibody; and detecting the content of the alpha-synuclein combined with the hemoglobin of Parkinson patients and normal healthy persons by utilizing an antigen-antibody reaction principle, and comparing.

The invention provides an anti-interference waistcoat for electrocardiogram monitoring. The anti-interference waistcoat comprises a waistcoat body. The waistcoat body comprises a front part and a back part. The shoulder position of the front part, a position on the left side of the chest of the front part, a position on the right side of the chest of the front part, the shoulder position of the back part, a position on the left side of the chest of the back part, and a position on the right side of the chest of the back part are connected together through connecting components. The anti-interference waistcoat for the electrocardiogram monitoring is convenient and comfortable to wear, is made of metal fiber blending materials or silver fiber blending materials or silver fiber fabric, can be divided into a single layer or double layers or three layers, and can effectively reduce interference caused by external reasons such as electromagnetic waves or static electricity at electrocardiogram monitoring time, reduce obsession of medical workers at electrocardiogram reading time, and improve the accuracy and diagnosis value of an electrocardiogram.

The invention discloses an anti-keratin antibody detection method and an anti-keratin antibody regent box, and belongs to the method for detecting the characteristics of blood in body. The method provided by the invention can be operated as follows: the esophagus of a bandicoot can be made into a biological thin slice which can be taken as an antigen and coated in the reaction region of a piece of slide glass; blood serum to-be-detected is added in the reaction region and then added with complement after the incubation, rinsing and drying in a spanning way, then added with the fluorescent markers of anti-complement antibodies after the incubation, rinsing and drying in a spanning way, and then observed under a fluorescence microscope after the incubation, rinsing and drying in a spanning way; if the horny layer appears typical and regular line-shaped or lamellar fluorescence, the detection result is positive. The regent box provided by the utility model is filled with regents, cover glass and slide glass with biological thin slices, such as negative control serum, positive control serum, condensed phosphate buffer solution and the application solution of the fluorescent markers of complement and anti-complement antibodies. The method provided by the invention is better than the prior method in indicators such as sensitivity, specificity, negative predictive value and positive predicative value, therefore, the method has higher diagnosis value in diagnosing rheumatoid diseases.

An X-ray image processing apparatus includes a site information determination unit configured to determine, based on discrete site information, continuous site information to be obtained by radiographing a moving image, an information acquisition unit configured to extract, from the discrete site information, image construction information, image processing method information, and X-ray exposure control method information, a computation unit configured to compute processing information about a site located between positions represented by the discrete site information using the information extracted by the information acquisition unit, an image processing unit configured to perform image processing based on the processing information which is computed by the computation unit, and an X-ray exposure control unit configured to perform X-ray exposure based on the processing information which is computed by the computation unit.

The invention discloses an exosome miRNA marker of rheumatoid arthritis and a kit and belongs to the technical field of biological detection. According to the exosome miRNA marker of rheumatoid arthritis, an exosome miR-204-5p sequence and a corresponding primer can be used for preparing a rheumatoid arthritis diagnostic kit; very high sensitivity and specificity are realized; and the exosome miRNA marker of the rheumatoid arthritis is beneficial for promoting the developments of early diagnosis, treatment predication and recurrence monitoring of the rheumatoid arthritis in China.

The invention relates to the technical field of medical biological detection, and particularly relates to serum miRNA markers suitable for early screening and diagnosis of ossification of the posterior longitudinal ligament and an application thereof in preparation of a diagnostic reagent or kit for ossification of the posterior longitudinal ligament. The biological markers miRNA-563, miRNA-196b, miRNA-10a and miRNA-129 having relatively high diagnosis value on ossification of the posterior longitudinal ligament are found out for the first time. Through development and application of the serum miRNA markers and the diagnostic kit, early screening of ossification of the posterior longitudinal ligament can be more convenient and easier to implement, the foundation is laid for clinicians to quickly and accurately grasp patient conditions and for improving the clinical treatment effect, and help is provided for finding out novel small-molecular drug targets having potential therapeutic value.

A diagnostic drug and a diagnostic kit for autoimmune diseases including at least one of a polypeptide selected from an HMG-1 family, a polypeptide selected from an HMG-2 family, a fragment thereof which is reactable with an antibody of an autoimmune disease patient, and a method for detecting an antibody of an autoimmune disease patient using the same are provided.

The invention discloses an exosome miRNA marker for early pregnancy diagnosis of sows and application of the exosome miRNA marker. The exosome miRNA molecular marker is prepared from ssc-miR-192, ssc-miR-146a-5p and ssc-miR-149; when the serum exosome miRNA is independently used for diagnosing and distinguishing early pregnant sows and non-pregnant sows, the areas under the ROC curve (AUC) are respectively 0.863, 0.885 and 0.857; the combined AUC of the ssc-miR-192 and the ssc-miR-146a-5p is 0.921; the combined AUC of the ssc-miR-192 and the ssc-miR-149 is 0.902; the combined AUC of the ssc-miR-146a-5p and the ssc-miR-149 is 0.910; when the three miRNAs, namely ssc-miR-192, ssc-miR-146a-5p and ssc-miR-149, are combined, the combined AUC is 0.959; The exosome miRNA molecular marker providedby the invention has high sensitivity and high specificity in early sow pregnancy diagnosis, and has excellent diagnostic performance by combining a plurality of miRNA markers.

The invention relates to an application of FLOT1 as a human ovarian cancer biomarker. It is confirmed that the ovarian cancer can be diagnosed through detecting the FLOT1 level of human serum, the cutoff value of the FLOT1 is 1233 pg / ml, the sensitivity is 0.722, the 1-specificity is 0.278, and the AUC value is 0.787, so the FLOT1 can be used as an effective biomarker of the ovarian cancer, and the diagnostic value is high; and it is also confirmed that the diagnosis rate of the ovarian cancer is improved by 24% by combining the FLOT1 with CA125 diagnosis. It is suggested that a reagent used for detecting the FLOT1 level of the serum can be used to prepare reagents or kits for diagnosing the ovarian cancer, and kits containing the serum FLOT1 and CA125 level detection reagent can significantly improve the diagnosis rate of the ovarian cancer. The application provides a new way for the accurate diagnosis of the ovarian cancer.

The invention discloses seven serum exosome micro-ribonucleic acids (miRNAs) related to diagnosis and treatment of liver cancer, and applications of the seven serum exosome miRNAs. The invention firstly discovers that hsa-miR-122, hsa-miR-125b, hsa-miR-145, hsa-miR-192, hsa-miR-194, hsa-miR-29a and hsa-miR-106a in serum exosomes can be used as biomarkers of the liver cancer, have a higher diagnostic value, provide a rapid and accurate diagnosis way for clinical use, and enable the diagnosis of the liver cancer to be more convenient and easier to implement. The invention also further discoversmatters for inhibiting specific miRNA, and the matters can inhibit the proliferation / growth of cells with the liver cancer, so that a foundation is laid for the clinic treatment of the liver cancer.

The invention relates to an application method for diagnosing an aptamer based on the conventional gel electrophoresis, and belongs to the technical field of the detection and analysis of biomedicine. The application method comprises the following steps of: incubating the aptamer and a blood serum sample, performing the conventional polyacrylamide gel electrophoresis and nucleic acid dyeing, observing a result under an ultraviolet lamp and collecting ultraviolet filtering images, measuring a gray-scale value of a dissociated aptamer strap by gel image analysis software, and analyzing difference between cases and contrast quantitatively to realize quantitative diagnosis. According to the application method, a liver cancer blood serum aptamer is used as a research model to be applied to liver cancer diagnosis, so the sensitivity, specificity and accuracy are up to over 90 percent. The application method is simple, convenient, easy, high in practical value and high in diagnostic efficiency, and has a bright application prospect.

The invention discloses an electrocardiogram monitoring power supply control system based on an electrocardio sensor. The system comprises a data collection terminal and a data monitoring terminal connected therewith, wherein the data collection terminal comprises an electrocardio sensor, an amplifying circuit, an analog-digital conversion module, a microcontroller module, a display module, a memory module, a DSP module, a wireless transmitter, a power control module, a power input module, a rectifying circuit and a voltage stabilizing circuit; the electrocardio sensor is connected with the microcontroller module through the amplifying circuit and the analog-digital conversion module in sequential connection; the display module, the memory module and the power control module are connected with corresponding ports of the microcontroller module; and the microcontroller module is connected with the wireless transmitter through the DSP module. The system disclosed by the invention integrates the advantages of existing electrocardiogram monitor and is small in volume and light in weight, has the advantages of concise operation interface, strong expandability and the like and realizes relatively high diagnosis value for various arrhythmias and heart diseases.

The invention provides a bone marrow smear atypical lymphocyte staining kit and an application method thereof, wherein the kit comprises a reagent tube filled with Polymer Helper, a reagent tube filled with PBS phosphate buffer solution, a reagent tube filled with antigen retrieval buffer, a reagent tube filled with hydrogen dioxide solution, a reagent tube filled with diaminobenzidine staining solution, a reagent tube filled with hematoxylin staining solution, a reagent tube filled with 1% acidulated alcohol, a reagent tube filled with 1% ammonium hydroxide, a reagent tube filled with xylene, a reagent tube filled with ethyl alcohol, a reagent tube filled with CD3 monoclonal antibody, a reagent tube filled with Pax-5 monoclonal antibody and a reagent tube filled with general type CD3 and Pax-5 immunohistochemical antibody and a packing box for separating and centrally packing the reagent tubes. According to the kit and the application method thereof, a bone marrow smear also can be used for carrying out the classification of lymphocyte, the value of bone marrow smear lymphoma diagnosis is greatly improved, and the technology is relatively simple, is easy to popularize and can be used for pathological diagnosis and therapeutic outcome judgment.

The invention discloses an application of serum protein HFREP1 in diagnosis of a rheumatoid arthritis disease state. Disease states of rheumatoid arthritis disease activity scoring systems DAS28 and RA recommended according to European anti-rheumatism alliance are divided into an activity period and a remission period. However, the DAS28 scoring system is a set of subjective scoring system and hashigh requirements for experience of doctors. According to the invention, the serum protein HFREP1 has extremely high diagnostic value in the aspect of diagnosing and distinguishing the active periodand the remission period of rheumatoid arthritis, is high in diagnostic accuracy, is objective and easy to operate compared with the existing DAS28 scoring system, and can be used for preparing a diagnostic kit for diagnosing and distinguishing the active period and the remission period of rheumatoid arthritis.

The invention provides a biomarker for early diagnosis and / or recurrence monitoring of brain glioma and an application of the biomarker, and belongs to the technical field of molecular diagnosis and molecular biology. Research of the invention discovers that the relative expression level of various miRNAs in the cerebrospinal fluid exosome is obviously related to glioma, the number of the miRNAs which are remarkably increased in the cerebrospinal fluid exosome of a glioma patient is 102, the number of the miRNAs which are remarkably decreased in the cerebrospinal fluid exosome of the glioma patient is 167, and the miRNAs and a marker spectrum which is composed of the miRNAs and contains 269 miRNAs have a high diagnosis value. Each of the 269 miRNAs can be independently used as a biomarkerof glioma, a marker spectrum set of the 269 miRNAs has a higher diagnostic value, and a rapid and accurate diagnostic mode is provided for clinic after combined application, so that diagnosis and recurrence detection of glioma are more convenient and easier to implement.

The invention provides a diagnosis index, a diagnosis model and a diagnosis system for schizophrenia. The diagnosis model comprises four key diagnosis indexes of fixed-point staring skewness peak time, face region fixation time, face region entering times and face region first fixation point fixation time. Compared with the prior art, the diagnosis model has the advantages that the diagnosis accuracy of schizophrenia is greatly improved, and a treatment scheme can be better formulated clinically.

A direct X-ray system for industrial radiography like non-destructive testing applications, and personal monitoring, being particularly less sensitive to pressure phenomena, has been disclosed, said system consisting of a direct X-ray black-and-white negative-working radiographic film material, comprised of a transparent support coated on at least one side thereof with a tabular grain emulsion layer, substantially free from spectrally sensitizing dyes, in which at least 50 percent of total grain projected area of all grains is accounted for by silver bromoiodide tabular grains having an iodide content of less than 5 mole %, based on silver, having an average aspect ratio of at least 2, and having a volume greater than 0.03 mum3, further characterized in that said tabular grain emulsion layer(s) comprise(s), in an amount of from 5 mg up to 100 mg per mole of coated silver bromoiodide at least one desensitizing agent having a hetero-aromatic part and an electron-withdrawing group and (2) disposed on opposite sides of the radiographic element, two intensifying screen sheets selected from the group consisting of lead, lead oxide, copper and steel, said screen sheets having been designed in order to emit electrons when exposed to X- or gamma-rays with an energy greater than or equal to 10 kVp.

The invention discloses a serum exosome hsa-miR-17-5p related to the diagnosis and treatment of cancers and application thereof. The invention first protects the application of a substance for assaying the hsa-miR-17-5p in the preparation of a product; and the function of the products is (c1) or (c2) as follows: (c1) identifying or helping to identify liver cancer cells; (c2) diagnosing or helpingto diagnose liver cancer. The invention further protects a primer group, which is prepared from a reverse transcription primer, a sense primer and an antisense primer; the reverse transcription primer is a single-chain DNA molecule shown as sequence 2 in a sequence table; the sense primer is a single-chain DNA molecule shown as sequence 3 in the sequence table; and the antisense primer is a single-chain DNA molecule shown as sequence 4 in the sequence table. The serum exosome hsa-miR-17-5p can serve as a biomarker for liver cancer, and has high diagnostic value, a rapid and accurate diagnostic method is provided for a clinic, and the diagnosis of liver cancer becomes more convenient and easier to implement.

The invention discloses an exosome miRNA marker for early pregnancy diagnosis of ewes and application of the exosome miRNA marker. The exosome miRNA molecular marker comprises oar-miR-22-3p and chi-miR-378-3p. The miRNA molecular marker shows high expression in serum exosomes of ewes in early pregnancy, and when the serum exosome miRNA is independently used for diagnosing and distinguishing the ewes in early pregnancy from the ewes in non-pregnancy, ROC area under the curve (AUC) is 0.891 (0.728, 1.000), 0.922 (0.791, 1.000), respectively; the AUC (95% CI) of the exosome miRNA molecular markeris 0.984 (0.936, 1.000) when early pregnant ewes and non-pregnant ewes are distinguished through combined diagnosis, it can be seen that the exosome miRNA molecular marker has high sensitivity and high specificity in early ewe pregnancy diagnosis, multiple miRNA markers are combined, and superior diagnosis performance is obtained.

In a method and apparatus for optimizing the signal-to-noise ratio (SNR) of a magnetic resonance (MR) dataset acquired by means of a magnetic resonance system having at least one transmit coil, a measurement protocol for an acquisition that is to be performed in order to obtain the MR dataset of a predefined measurement volume. A deviation of an actual flip angle from the predefined flip angle in a specific area of the predefined measurement volume is determined for a preset transmitter scaling. The transmitter scaling of the RF pulse is adjusted in order to correct the actual flip angle so that the actual flip angle is approximated to the predefined flip angle in the specific area. The MR dataset is acquired with the adjusted transmitter scaling.